Phaseline

Companies › Guangzhou Virotech Pharmaceutical

Guangzhou Virotech Pharmaceutical: clinical trials, targets and expected readouts

3 active drug programs in 58 registered trials: 42 Phase 2, 9 Phase 3, 7 Phase 1; Oncology, Other; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VRT106
Recombinant oncolytic virus M1
–Phase 2Diffuse Midline Glioma, H3 K27M-Mutant; HCC; Solid Tumor; Solid Tumors …Sep 2027
Rivoceranib
Vascular endothelial growth factor receptor 2 inhibitor
KDRPhase 2HCC; Hepatocellular Carcinoma; Advanced Breast Cancer; Acral Melanoma …Dec 2028
M1-c6v1–Phase 1Solid TumorJun 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04560127RivoceranibPhase 2Radioactive Iodine-refractory Differentiated Thyroid CancerOncologyDec 2025
NCT06429696RivoceranibPhase 2Small Cell Lung Cancer Extensive StageOncologyApr 2026
NCT06349317RivoceranibPhase 2Hepatocellular CarcinomaOncologyMay 2026
NCT05198609RivoceranibPhase 3Hepatocellular CarcinomaOncologyJul 2026
NCT05139095RivoceranibPhase 2Gestational Trophoblastic NeoplasiaOtherDec 2026
NCT05451290RivoceranibPhase 2Advanced Biliary Tract CarcinomaOncologyDec 2026
NCT04208347RivoceranibPhase 2Gastric and Gastroesophageal Junction (GEJ) AdenocarcinomaOncologyDec 2026
NCT06576973RivoceranibPhase 2Esophageal Squamous Cell CarcinomaOncologyDec 2026
NCT06454578RivoceranibPhase 2Carcinoma, HepatocellularOncologyDec 2026
NCT04331093RivoceranibPhase 2Acral MelanomaOncologyDec 2026
NCT06749730RivoceranibPhase 2Unresectable Biliary Tract CarcinomaOncologyDec 2026
NCT06475209RivoceranibPhase 2SCLCOncologyDec 2026
NCT05062837RivoceranibPhase 2Hepatocellular CarcinomaOncologyDec 2026
NCT06099821RivoceranibPhase 2Digestive System CancersOncologyDec 2026
NCT06831175RivoceranibPhase 2Adrenal Cortical CarcinomaOncologyDec 2026
NCT05447702RivoceranibPhase 2Triple Negative Breast CancerOncologyDec 2026
NCT06700421RivoceranibPhase 2Unresectable Locally Advanced Non-small Cell Lung CancerOncologyDec 2026
NCT06418594RivoceranibPhase 2HER2-negative Breast Cancer Brain MetastasesOncologyDec 2026
NCT06447623RivoceranibPhase 3Advanced Breast CancerOncologyFeb 2027
NCT05789043RivoceranibPhase 3Acral MelanomaOncologyFeb 2027
NCT06296563RivoceranibPhase 2Intrahepatic CholangiocarcinomaOncologyMar 2027
NCT07479732RivoceranibPhase 1OsteosarcomaOncologyMar 2027
NCT06360042RivoceranibPhase 2Unresectable Hepatocellular CarcinomaOncologyMar 2027
NCT05699655RivoceranibPhase 2Immunotherapy Gastrict CancerOncologyApr 2027
NCT06913777RivoceranibPhase 3Neoadjuvant TherapyOtherApr 2027
NCT06792162RivoceranibPhase 2Gastric CancerOncologyApr 2027
NCT07157969RivoceranibPhase 2HCC - Hepatocellular CarcinomaOncologyJun 2027
NCT07135544RivoceranibPhase 2Biliary Tract CancerOncologyJun 2027
NCT05759572RivoceranibPhase 2Breast Cancer MetastaticOncologyJul 2027
NCT07105748RivoceranibPhase 2Mixed Hepatocellular-cholangiocarcinomaOncologyAug 2027
NCT06607770RivoceranibPhase 1Lung CancerOncologyAug 2027
NCT04072042RivoceranibPhase 2SarcomaOncologySep 2027
NCT06368921VRT106Phase 1Solid TumorOncologySep 2027
NCT07289997RivoceranibPhase 2AFP Gastric or Gastroesophageal Junction AdenocarcinomaOncologySep 2027
NCT05854849RivoceranibPhase 3Nasopharyngeal CarcinomaOncologyDec 2027
NCT06749691RivoceranibPhase 2Small Cell Lung Cancer Extensive StageOncologyDec 2027
NCT06925243RivoceranibPhase 3Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ])OncologyDec 2027
NCT06693128RivoceranibPhase 2Gastric and Gastroesophageal Junction (GEJ) AdenocarcinomaOncologyDec 2027
NCT07311408RivoceranibPhase 2Gastric Cancer (GC)OncologyJan 2028
NCT07353684RivoceranibPhase 2AdebrelimabOncologyFeb 2028
NCT07687433RivoceranibPhase 2Rectal Cancer PatientsOncologyMay 2028
NCT07589257VRT106Phase 2Diffuse Midline Glioma, H3 K27M-MutantOncologyJun 2028
NCT06485466RivoceranibPhase 3Unresectable Hepatocellular CarcinomaOncologyJun 2028
NCT05069857RivoceranibPhase 2Oral Squamous Cell CarcinomaOncologyJun 2028
NCT06046742M1-c6v1Phase 1Solid TumorOncologyJun 2028
NCT06826313VRT106Phase 1Solid TumorsOncologyDec 2028
NCT07569679RivoceranibPhase 2Biliary Tract CancerOncologyDec 2028
NCT07589244VRT106Phase 2HCCOncologyDec 2028
NCT07093814VRT106Phase 1GlioblastomaOncologyDec 2028
NCT07589244RivoceranibPhase 2HCCOncologyDec 2028
NCT06181032RivoceranibPhase 1Biliary Tract MalignanciesOncologyFeb 2029
NCT06438627RivoceranibPhase 3Nasopharyngeal CarcinomaOncologyMay 2029
NCT07267806RivoceranibPhase 3Hepato Cellular Carcinoma (HCC)OncologyOct 2029
NCT07026149RivoceranibPhase 2Gastric and Gastroesophageal Junction (GEJ) AdenocarcinomaOncologyMay 2030
NCT02485015RivoceranibPhase 2Stomach NeoplasmsOncologyJun 2030
NCT02493582RivoceranibPhase 2Adenocarcinoma of LungOncologyJul 2030
NCT04666090RivoceranibPhase 2Esophageal Squamous Cell CarcinomaOncologyNov 2030
NCT03982485RivoceranibPhase 2Breast CancerOncologyMar 2031

Targets

KDR (1)

Companies with the same targets

Hutchmed Exelixis Merck & Co. (MSD) Jiangsu HengRui Medicine Chia Tai Tianqing Pharmaceutical Group Takeda AO GENERIUM Chipscreen Biosciences Avalyn Pharma Mannkind

Companies built like this

GrandPharma (China) Criterium Diakonos Oncology Vyriad HRYZ Biotech

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.